DEVELOPMENT OF NOVEL MICROSTRUCTURED LIPID CARRIERS FOR DISSOLUTION RATE ENHANCEMENT OF ALBENDAZOLE
Objective: This study aimed to develop a microstructured lipid carrier that improves the rate of dissolution of the active pharmaceutical ingredient (API) Albendazole.
Methods: A solvent diffusion method was used for the development of microstructured lipid carriers. The developed carriers were characterized by optical microscopy, infrared spectroscopy, differential scanning calorimetry (DSC), X-ray diffractometry (XRD), and dissolution testing.
Results: The morphology of the carriers was irregular, and their size tends to decrease with the addition of modifiers. Furthermore, the diffractograms and the thermograms indicated a loss of crystallinity. The thermograms and infrared spectra showed that there are not chemical incompatibilities between the API and the excipients. When the lipid carrier particles were modified with Aerosil® 200 (specifically when using this excipient at a level of 6% w/w), dissolution was increased up to 85.96±1.17 % of the drug content as per USP test for Albendazole tablets in comparison with 36.13±0.52 % for a lipid carrier formulation without modifiers.
Conclusion: It was demonstrated that it is possible to develop a modified lipid carrier that improves the dissolution rate of an API with a low solubility, which was related to the amorphization of the API crystalline structure.
2. Bhoyar PK, Morani DO, Biyani DM, Umekar MJ, Mahure JG, Amgaonkar YM. Encapsulation of naproxen in lipid-based matrix microspheres: characterization and release kinetics. J Young Pharm 2011;3:105–11.
3. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems–an overview. Acta Pharm Sin B 2013;3:361–72.
4. Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Delivery Rev 2008;60:734–46.
5. Mayet L, Jung Cook H, Mendoza O, Rodriguez J. Estudio comparativo de perfiles de disolución de medicamentos del mercado nacional. Rev Mex Cienc Farm 2008;39:4–8.
6. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 2006;314:83–9.
7. United States Pharmacopeial Convention. USP 40/NF35. Rockville (MD); 2017.
8. Albertini B, Passerini N, Gonzalez Rodriguez ML, Perissutti B, Rodriguez L. Effect of Aerosil® on the properties of lipid controlled release microparticles. J Controlled Release 2004;100:233–46.
9. Rowe R, Sheskey P, Quinn M. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press and American Pharmacists Association; 2009.
10. Susarla R, Afolabi A, Patel D, Bilgili E, Dave RN. Novel use of superdisintegrants as viscosity enhancing agents in biocompatible polymer films containing griseofulvin nanoparticles. Powder Technol 2015;285:25–33.
11. Padhye SG, Nagarsenker MS. Simvastatin solid lipid nanoparticles for oral delivery: formulation development and in vivo evaluation. Indian J Pharm Sci 2013;75:591–8.
12. Albertini B, Passerini N, Gonzalez Rodriguez ML, Perissutti B, Rodriguez L. Effect of Aerosil® on the properties of lipid controlled release microparticles. J Controlled Release 2004;100:233–46.
13. Alanazi FK, El-Badry M, Ahmed MO, Alsarra IA. Improvement of albendazole dissolution by preparing microparticles using spray-drying technique. Sci Pharm 2007;75:63–79.
14. Gonzalez N, Castro S, Sanchez B, Allemandi D, Palma S. Albendazole solid dispersions: influence of dissolution medium composition on in vitro drug release. Dissolution Technol 2014;21:42-7.
15. Yurkanis P. Espectrometria de masas, espectroscopia infrarroja y espectroscopia ultravioleta/visible. In: Cruz L. editor. Quimica Organica. 5th ed. México: Pearson Educacion; 2008. p. 512–55.
16. Pavia DL, Lampman GM, Kriz GS, Vyvyan JR. Introduction to spectroscopy. 4th ed. United States of America: Cengage Learning; 2008.
17. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surfaces B 2005;45:167–73.
18. Herrmann S, Winter G, Mohl S, Siepmann F, Siepmann J. Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J Controlled Release 2007;118:161–8.
19. Mani N, Suh HR, Jun HW. Microencapsulation of a hydrophilic drug into a hydrophobic matrix using a salting?out procedure. II. Effects of adsorbents on microsphere properties. Drug Dev Ind Pharm 2004;30:83–93.
20. Castro Ruiz JM. Diseno de un sistema bioadhesivo de clorhexidina empleando pullulan como matriz para uso en mucosa oral. Colombia: Universidad Nacional de Colombia; 2014.
21. Hernandez Torres JE, Melgoza Contreras LM. Principales superdisgregantes sintéticos, mecanismos y factores que influyen en su actividad. Rev Colomb Ciencias Quimico Farmaceuticas 2014;43:234–47.
22. Mohanachandran PS, Sindhumol PG, Kiran TS. Superdisintegrants: an overview. Int J Pharm Sci Rev Res 2011;6:105–9.
23. Shihora H, Panda S. Superdisintegrants, utility in dosage forms: a quick review. J Pharm Sci Biosci Res 2011;1:148–53.
24. Yu LX, Furness MS, Raw A, Woodland Outlaw KP, Nashed NE, Ramos E, et al. Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm Res 2003;20:531–6.
This work is licensed under a Creative Commons Attribution 4.0 International License.